China says WHO gave go-ahead for coronavirus vaccine emergency use program

The World Health Organization gave China its support and understanding to start administering experimental coronavirus vaccines to people while clinical trials were still underway, a Chinese health official said on Friday.

China launched its emergency program in July, having communicated with the WHO in late June, according to Zheng Zhongwei, a National Health Commission official.

For more coronavirus news, visit our dedicated page.

Hundreds of thousands essential workers and other limited groups of people considered at high risk of infection have been given the vaccine, even though its efficacy and safety had not been fully established as Phase 3 clinical trials were incomplete.

“At end-June, China’s State Council approved a plan of COVID-19 emergency use program,” Zheng told a news conference.

“After the approval, on June 29, we made a communication with the relevant representatives of the WHO Office in China, and obtained support and understanding from WHO,” Zheng said.

For all the latest headlines follow our Google News channel online or via the app

WHO’s representative in China did not immediately respond to a request for comment.

WHO chief scientist Soumya Swaminathan said in Geneva this month that national regulatory authorities could approve use of medical products within their own jurisdictions in the current emergency situation, but described that as a “temporary solution.”

Read more:

Coronavirus vaccine tested on 90 pct of China’s Sinovac employees, families, says CEO

China’s Sinovac coronavirus vaccine approved for emergency use: Source

Coronavirus: Scientists see downsides to top COVID-19 vaccines from Russia, China

The long-term solution lay in completion of Phase 3 trials, the WHO official said.

Beijing has not publicly released full details of its emergency use program.

At least three vaccination candidates, including two developed by state-backed China National Biotec Group (CNBG) and one from Sinovac Biotech, all in Phase 3 trials overseas, are included in the emergency use program.

A fourth experimental vaccine developed by CanSino Biologics were approved to be used in the Chinese military in June.